LH
T2Labcorp Holdings Inc.
Data Owners '25: Healthcare, Claims & Clinical DataMedTech Long '24: Lab Research & TrialsMedTech Long '26: CROsMedTech Long '26: Diagnostics & Early Detection
OverviewLabcorp Holdings Inc. (LH) provides vital diagnostic laboratory services, representing approximately 80% of its revenue, and biopharmaceutical laboratory servic
Labcorp Holdings Inc. (LH) provides vital diagnostic laboratory services, representing approximately 80% of its revenue, and biopharmaceutical laboratory services, accounting for roughly 20%. The company serves medical professionals, healthcare facilities, pharmaceutical firms, and patients. Labcorp is strategically expanding its specialty testing in areas like oncology and neurology, growing its consumer health offerings, and leveraging AI and robotics to enhance operations and customer experience.
- What They Do (Plain English & Analogies)
- Labcorp acts as a central hub for a wide range of medical tests and drug development support. When your doctor needs to understand what's happening inside your body, Labcorp performs those essential lab tests, like blood work or urine analysis, to provide clear and accurate results. They also partner with pharmaceutical companies, serving as a specialized research collaborator, helping them develop new medicines by conducting tests during clinical trials. So, whether it's for your personal health diagnosis or for bringing new drugs to market, Labcorp provides the critical laboratory services and data necessary for informed decisions.
- Very Brief History
- Labcorp's origins trace back to 1969 as Biomedical Reference Laboratories in Burlington, North Carolina. The company, as it is largely known today, was formed in 1995 through the merger of Roche Biomedical Laboratories and National Health Laboratories, establishing a national diagnostics platform. A significant expansion occurred in 2015 with the acquisition of Covance, which broadened Labcorp's reach into drug development services. In 2023, Labcorp spun off its clinical development business, Fortrea, to focus on its core diagnostics and lab-enabled drug development services.
- "Street Stereotype"
- Labcorp is generally perceived by investors and analysts as a diversified leader in laboratory services, combining a massive diagnostic testing network with significant central laboratory capabilities for drug development. While it benefits steadily from rising overall clinical volume and strategic acquisitions, its broad diagnostic hospital network is seen as softening its "pure-play CRO" (Contract Research Organization) torque, meaning it's not solely focused on clinical trials like some competitors. It is viewed as a stable, large-scale player in healthcare testing and research, increasingly leveraging technology like AI.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Labcorp's customers span various sectors including medical professionals (physicians and other healthcare providers), healthcare facilities (hospitals and health systems), pharmaceutical and biotechnology firms (pharmaceutical, biotechnology, medical device, and diagnostics companies, and CROs), scientific investigators (researchers and academic institutions), patients and consumers (individuals seeking direct-to-consumer testing), governmental agencies, employers, and crop protection and chemical companies. Example clients and partners mentioned include Children's Hospital of Philadelphia (CHOP), Crouse Health, Parkview Health, Illumina, Merck, Amazon Web Services (AWS), Datavant, and Optum.ai.
- New Customers / Segments They'Re Targeting
- Labcorp is actively targeting several new customer sets and expanding into strategic segments. They aim to be a "partner of choice" for health systems and regional/local laboratories, expanding their patient and provider networks through collaborations and acquisitions. The company is also focused on leading in high-growth specialty testing areas such as oncology, women's health, neurology (especially Alzheimer's testing), and autoimmune disease. Furthermore, Labcorp is expanding its direct engagement with consumers through initiatives like Labcorp OnDemand and the new MyLabcorp mobile app, offering customizable health tests and personalized health data insights.
- Supply Chain And Sourcing Geographies
- Labcorp's supply chain is global and complex, supporting its extensive laboratory operations and clinical trial services. It involves sourcing instruments, reagents, consumables, specimen-collection materials, software, and logistics services. The company has a global supply chain sourcing and procurement team that works with manufacturers, distributors, and logistics partners across the U.S., Europe, and Asia to ensure a reliable supply for its operations, including the production of customized clinical trial kits. Specific sourcing geographies are not detailed in the provided text, but given its global operations and the nature of laboratory supplies, it is highly probable that components and materials are sourced from a diverse range of countries, including those with significant manufacturing capabilities in medical devices and chemicals. The company's efforts to mitigate supply chain disruptions during the COVID-19 pandemic highlight a global network of manufacturers and distributors.
- Sales Geographies And Expansion Plans
- Labcorp operates one of the largest clinical laboratory networks globally, with operations in over 100 countries, although its primary operations are in the U.S.. Its global performing and processing labs are located around the world, with more than 30 U.S. reference and specialty labs dedicated to diagnostic testing and over 75 global labs primarily dedicated to research, development, and clinical trial testing. The company serves customers in the Americas, Europe, and Asia-Pacific. Regarding expansion plans, Labcorp is actively pursuing acquisitions and partnerships with health systems and regional/local laboratories within the U.S. to expand its patient and provider networks and increase access to its test portfolio, indicating an "active pipeline of hospitals and regional local laboratory deals." While the transcript does not explicitly detail new country-level geographic sales expansion plans, the ongoing growth in its Biopharma Laboratory Services (BLS) segment, which has a global footprint, implies continued expansion and service delivery in existing international markets for clinical trials.
- How Key Themes May Help/Hurt
- Labcorp is positioned within the "MedTech Long '26: CROs" theme, which generally presents a bullish outlook for the company, though with some caveats. The theme's bullish drivers, such as a robust biotech funding recovery and increased R&D investment by large pharmaceutical companies, directly benefit Labcorp's massive central laboratory network, which is vital for global trial biomarker testing. Additionally, the strategic investments in advanced technologies like Agentic AI platforms, highlighted in the theme, align perfectly with Labcorp's own initiatives in AI and digital pathology, driving new service offerings and long-term growth. Conversely, the theme's bearish aspects could hurt Labcorp. Overall macroeconomic conditions and budgetary uncertainties could pressure R&D spending, potentially impacting Labcorp's biopharma services. The highly competitive CRO market, characterized by aggressive pricing dynamics, could also pressure margins in its Biopharma Laboratory Services segment. Lastly, industry-wide volatility in net bookings and elevated cancellation rates, while Labcorp's trailing 12-month book-to-bill remains healthy, could diminish long-term revenue visibility.
3 Main Long-Term Bull Details
- Labcorp's strategic focus and market-leading portfolio in high-growth specialty areas such as oncology (liquid biopsies, MRD solutions), neurology (Alzheimer's testing), autoimmune disease, and women's health position it for accelerated growth, as these segments are expected to grow 2-3x faster than the broader diagnostics market.
- The company's strategy of being a "partner of choice" for health systems and regional/local laboratories, coupled with an active pipeline of such deals, enables it to continuously expand its patient and provider networks, increase access to its broad test portfolio, and drive volume growth.
- Labcorp's significant investments and collaborations in advanced technologies, including AI and robotics, are enhancing customer experiences, improving operational efficiency (e.g., digital pathology, streamlined operations), and accelerating drug discovery (e.g., AI-powered real-world data for Alzheimer's research), creating a sustainable competitive advantage and driving future growth.
3 Main Long-Term Bear Details
- Ongoing regulatory changes and initiatives like PAMA (Protecting Access to Medicare Act) and CRUSH (CMS's initiative to reduce fraud, waste, and abuse) pose potential headwinds. While Labcorp aims to comply, these could impact reimbursement rates and create uncertainty, potentially affecting profitability, especially in the diagnostics segment.
- Both the diagnostics and biopharma laboratory services markets are highly competitive. Aggressive pricing dynamics, particularly in the CRO market, could pressure margins and make it challenging to maintain market share, despite Labcorp's scale and differentiation.
- While biotech funding is recovering, broader macroeconomic conditions and budgetary uncertainties can still impact R&D spending, leading to potential fluctuations in demand for Labcorp's biopharma services and overall organic revenue growth.
- Competitors And Differentiation
- Labcorp operates in a competitive landscape across both its diagnostics and biopharma laboratory services segments. Key competitors in diagnostics include Quest Diagnostics and various regional and hospital-based laboratories, as well as specialty diagnostics companies like Exact Sciences and Natera in specific testing areas. In biopharma laboratory services, competitors include other Contract Research Organizations (CROs) with central lab capabilities such as IQVIA, ICON plc, Charles River Laboratories, Thermo Fisher Scientific (PPD), Medpace, and Fortrea (its spin-off). Labcorp differentiates itself through a comprehensive service offering that combines routine and specialty diagnostic tests with extensive biopharma laboratory services, acting as a "one-stop shop." The company emphasizes its scientific leadership in high-growth specialty testing areas like neurology (especially Alzheimer's), oncology, autoimmune disease, and women's health, noting its role in supporting a high percentage of new FDA-approved drugs. Its extensive global network and strategic partnerships with health systems further enhance its reach and access. Furthermore, Labcorp is making significant investments in advanced technologies, including AI and robotics, to improve customer experiences, operational efficiency (e.g., digital pathology, AI-powered real-world data platforms), and accelerate drug discovery. It is also expanding consumer engagement through platforms like Labcorp OnDemand and MyLabcorp.
- Recent Performance & What The Market'S Focused On
- Labcorp reported a strong start to 2026, with Q1 enterprise revenue reaching $3.5 billion, an increase of 6% year-over-year. Margins improved by over 30 basis points, and adjusted earnings per share grew 11%. Diagnostics revenue increased 5%, and Biopharma Laboratory Services revenue increased 8%, driven by 11% growth in central labs (or 5% organic constant currency). The company raised the midpoint of its full-year 2026 enterprise revenue and adjusted EPS guidance. The market is focused on organic growth and margin expansion, particularly the continued momentum in both Diagnostics and Central Laboratory businesses. Key areas of attention also include progress in strategic growth priorities like partnerships with health systems and leadership in specialty testing, the successful implementation and ROI of AI and robotics, the health of BLS bookings and backlog, and the potential impact of regulatory changes like PAMA and CRUSH initiatives.
- Revenue Segments And Estimated Mix
- Diagnostics — Mix: ~80% (Q1 2026 revenue of $2.8 billion out of $3.5 billion total); Source: Q1 2026 transcript; Trend: Increased 5% YoY, with 2.9% organic growth
- Biopharma Laboratory Services (BLS) — Mix: ~20% (Q1 2026 revenue of $781 million out of $3.5 billion total); Source: Q1 2026 transcript; Trend: Increased 8.2% YoY, with 3.7% organic growth; Central Labs grew 11% (5% organic constant currency)
- Product Brands
- Labcorp OnDemand
- MyLabcorp
- Labcorp Fentanyl Urine Visual Test
- Integrated Genetics
- Integrated Oncology
Bull / Bear DetailsLabcorp (LH) is well-positioned for durable growth, driven by strong performance in its diversified diagnostic and biopharma laboratory services. Strategic expa
Thesis
Labcorp (LH) is well-positioned for durable growth, driven by strong performance in its diversified diagnostic and biopharma laboratory services. Strategic expansion in high-growth specialty testing (oncology, neurology), active hospital partnerships, and significant AI/robotics integration are enhancing efficiency and customer experience. While competitive pricing and regulatory uncertainties persist, robust organic growth and a healthy BLS backlog support a positive outlook as of July 24, 2026.
Bull case
Labcorp delivered robust Q1 2026 results with enterprise revenue up 5.8%, adjusted EPS growing 11%, and operating margins expanding. Management raised full-year 2026 guidance for both revenue and EPS, reflecting confidence in continued profitable growth and disciplined capital deployment. This demonstrates strong operational execution and positive momentum across its diversified businesses.
The company is achieving double-digit growth in key specialty areas like neurology (driven by Alzheimer's testing) and oncology (liquid biopsies, MRD solutions), which are expected to grow 2-3x faster than the broader diagnostics market. An active pipeline of hospital and regional lab acquisitions and collaborations further expands its patient and provider networks, driving volume growth.
Labcorp is aggressively leveraging AI and robotics to enhance customer experiences and operational efficiency. Initiatives include digital pathology deployment, an AI-powered real-world data platform for Alzheimer's research with AWS/Datavant, and AI for streamlining lab operations and patient engagement via the MyLabcorp app. These investments drive innovation and long-term competitive advantage.
Bear case
The CRO market remains highly competitive, characterized by "knife fight every quarter" pricing dynamics that can impact margins. In the consumer health segment, Labcorp is selectively choosing not to compete in some areas due to aggressive pricing and uncertainty regarding pricing floors, indicating ongoing competitive challenges and potential pressure on profitability.
The future impact of PAMA on reimbursement rates for laboratory testing remains a significant regulatory uncertainty. The actual effect on Labcorp will depend heavily on the participation rate of other laboratories, including hospital labs, in the upcoming PAMA data reporting survey, creating potential headwinds and less favorable rates if participation is low.
While Q1 2026 saw strong performance, adverse weather conditions had an estimated $15 million impact on revenue, constraining organic volume growth in Diagnostics. Although management does not explicitly bake in future weather assumptions, such unpredictable external factors could continue to pose risks to volume and revenue, potentially impacting full-year guidance.
Bull / Bear Case
- Bear Case
- The CRO market remains highly competitive, characterized by aggressive pricing dynamics that can impact margins. In the consumer health segment, Labcorp is selectively choosing not to compete in some areas due to aggressive pricing and uncertainty regarding pricing floors, indicating ongoing competitive challenges. A significant regulatory uncertainty persists with PAMA, where the actual impact on reimbursement rates for laboratory testing in 2027 will heavily depend on the participation rate of other laboratories in the ongoing data reporting survey. Low participation could lead to less favorable rates, creating potential headwinds and impacting profitability. Additionally, adverse weather conditions in Q1 2026 had an estimated $15 million impact on revenue, constraining organic volume growth in Diagnostics, highlighting vulnerability to unpredictable external factors.
- Bull Case
- Labcorp delivered robust Q1 2026 results, with enterprise revenue up 5.8% and adjusted EPS growing 11%, leading to a raised full-year 2026 guidance. The company is strategically expanding in high-growth specialty areas like neurology (driven by Alzheimer's testing) and oncology (liquid biopsies, MRD solutions), which are expected to grow 2-3x faster than the broader diagnostics market. An active pipeline of hospital and regional lab acquisitions and collaborations, such as with Children's Hospital of Philadelphia, is expanding its patient and provider networks, driving volume growth. Furthermore, Labcorp is aggressively leveraging AI and robotics to enhance customer experiences and operational efficiency, including digital pathology deployment and an AI-powered real-world data platform for Alzheimer's research, creating a sustainable competitive advantage and supporting long-term growth.
- More Compelling & Why
- Bear. While Labcorp shows strong operational execution and growth in specialty areas, its current valuation, with a TTM P/E of approximately 24-25x, appears to price in much of this growth. The most compelling bear argument is the unresolved PAMA uncertainty, with potential CLFS cuts of up to 15% on 800 tests starting January 2027 if the RESULTS Act doesn't pass. This regulatory headwind, coupled with intense competitive pricing, poses a significant risk to future profitability. My view would flip to Bull if the RESULTS Act were passed, providing long-term PAMA stability, or if the company demonstrated substantial margin expansion driven by AI efficiencies that significantly outpaced current expectations.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Biopharma Laboratory Services (BLS) Segment Quarterly Book-to-Bill Ratio | This ratio is a leading indicator of future revenue and demand for Labcorp's contract research services, directly impacting the growth and backlog of its profitable Central Labs business. | The reported BLS quarterly book-to-bill ratio in Q2 2026 earnings and subsequent quarters. Management expects sequential improvement in Q2 2026 from 0.94 and for the trailing 12-month ratio to remain above 1.0 for the full year. | Bullish if Q2 2026 quarterly book-to-bill improves sequentially from 0.94 and the trailing 12-month book-to-bill remains at or above 1.0. Bearish if the quarterly book-to-bill declines or fails to improve, or if the trailing 12-month ratio falls below 1.0. | Labcorp's Q2 2026 earnings release and conference call transcript (expected late July/early August 2026). | Industry analyst reports on CRO bookings trends; aggregated data from major CRO earnings reports (e.g., IQVIA, ICON, Medpace). | Bloomberg Terminal: Company earnings transcripts for keyword searches on 'book-to-bill', 'backlog', 'bookings'. |
| Progress on Hospital & Regional Lab Acquisitions and Partnerships | These strategic deals expand Labcorp's patient and provider networks, increase access to its broad test portfolio, and drive volume growth, which is crucial for the Diagnostics segment's long-term strategy and market share. | Announcements regarding the closing of the Parkview Health acquisition (expected 'in the very near future') and any new strategic collaborations or acquisitions from the 'active pipeline' mentioned by management. | Bullish if the Parkview Health acquisition closes as expected and if new, significant hospital or regional lab deals are announced. Bearish if announced deals are delayed or if no new material partnerships are disclosed from the active pipeline. | Labcorp's press releases, SEC filings (Form 8-K for material acquisitions), and future earnings call transcripts. | Local news outlets in Indiana/Northwest Ohio for Parkview Health acquisition updates; healthcare industry news sites for partnership announcements. | S&P Capital IQ: M&A deal flow for healthcare diagnostics; MergerMarket: Healthcare sector M&A activity. |
| PAMA Data Reporting Survey Participation and RESULTS Act Progress | High participation in the PAMA survey by a broad range of laboratories, especially lower-cost providers, could mitigate the negative impact of PAMA on Labcorp's reimbursement rates in future years. The RESULTS Act aims for a long-term, permanent fix to PAMA. | Updates from CMS or industry trade groups (ACLA) on the number and type of laboratories submitting PAMA data (survey started April 30, 2026). Progress on the RESULTS Act, including a CBO score and CMS technical assistance. | Bullish if a significant number of hospital and other laboratories report PAMA data, indicating a broader and potentially more favorable market-based rate calculation for future PAMA updates. Bullish if the RESULTS Act gains legislative traction (e.g., positive CBO score). Bearish if participation in the PAMA survey is low, potentially leading to less favorable reimbursement rates for Labcorp in the future, or if the RESULTS Act stalls. | CMS announcements, ACLA press releases and advocacy updates, congressional news regarding healthcare legislation, Labcorp's future earnings calls for management commentary. | ACLA website for advocacy updates; Congress.gov for RESULTS Act legislative status. | FiscalNote: Legislative tracking and lobbying activity related to the RESULTS Act and PAMA. |
| MyLabcorp App Launch and Consumer Health Business Growth | The MyLabcorp app, launching in May 2026, enhances customer experience and engagement, potentially driving repeat business and expanding the direct-to-consumer channel, which is a strategic growth priority with double-digit growth. | Management commentary on MyLabcorp app adoption rates, user engagement metrics, and continued double-digit revenue growth for the Consumer Health segment in Q2 2026 and beyond. | Bullish if MyLabcorp app launch is smooth with strong initial user adoption and positive feedback, and if Consumer Health maintains or accelerates its double-digit growth. Bearish if app adoption is slow or if Consumer Health growth decelerates. | Labcorp's Q2 2026 earnings release and conference call transcript; company press releases regarding app launch and features. | App store reviews and ratings for MyLabcorp; Google Trends: 'MyLabcorp app' or 'Labcorp OnDemand' search volume. | Sensor Tower/App Annie: App download and usage statistics for MyLabcorp; Similarweb: Web traffic to Labcorp OnDemand. |
| Growth in Specialty Diagnostics (Oncology, Neurology, Autoimmune Disease, Women's Health) | These high-growth, higher-margin specialty areas are expected to grow 2-3 times faster than the broader diagnostics market, driving overall Diagnostics segment revenue, price/mix, and margin expansion. | Commentary in future earnings calls on specific growth rates for neurology (especially Alzheimer's testing) and oncology (liquid biopsy, MRD solutions) testing, new test launches, and expanded access initiatives (e.g., collaborations with Illumina). | Bullish if neurology and oncology testing continue to show strong double-digit growth, and if new, high-value specialty tests are launched or gain significant market traction. Bearish if growth in these key areas decelerates or if competitive pressures impact market share. | Labcorp's quarterly earnings releases and conference call transcripts; investor presentations. | ClinicalTrials.gov: New trials involving specific biomarkers or conditions (e.g., Alzheimer's, liquid biopsy); FDA approvals/clearances for new diagnostic tests. | DeciBio: Market share and growth rates for specific diagnostic test categories; EvaluatePharma: Drug development pipeline and associated diagnostic needs. |
Key Reported Metrics, Reratings Triggers & ResultsThis metric indicates the health and growth of Labcorp's contract research business, a key driver for the CRO theme. Strong organic growth signals robust demand
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Biopharma Laboratory Services (BLS) Revenue Growth (Organic Constant Currency) | 3.7% | This metric indicates the health and growth of Labcorp's contract research business, a key driver for the CRO theme. Strong organic growth signals robust demand and successful execution in Central Labs. | For Labcorp's stock to rerate higher, its Biopharma Laboratory Services (BLS) Revenue Growth (Organic Constant Currency) metric needs to hit at least 4.5% in Q2 2026. This would represent an acceleration from the current 3.7% and exceed the implied upper end of the company's full-year 2026 guidance range (approximately 3.9% organic constant currency, derived from the 3.8%-5.4% total BLS growth guidance which includes a 1.5% foreign currency tailwind). Additionally, a strong BLS quarterly book-to-bill ratio above 1.0, demonstrating sequential improvement from Q1's 0.94, is crucial to signal future revenue growth. Peer performance, such as Medpace's 17% YoY revenue growth and 1.13x book-to-bill, sets a high bar for the CRO sector, making an accelerated organic growth rate for Labcorp's BLS particularly impactful. | Accelerated BLS organic constant currency growth signals robust demand and effective execution in Labcorp's drug development services, particularly Central Labs. This validates the company's strategic focus and competitive strength in the highly competitive CRO market, indicating strong backlog conversion and future revenue visibility. Exceeding expectations would reinforce the investment thesis, potentially leading to a higher valuation. | |
| Adjusted EPS Growth | 10.6% | Adjusted EPS growth is a key bottom-line metric reflecting the company's overall profitability, operational efficiency, and ability to translate revenue growth into shareholder value. | Labcorp Holdings Inc. (LH) would likely need to report Q2 2026 Adjusted EPS growth significantly above the 10.1% consensus estimate, ideally in the mid-teens (e.g., 14-15% or higher). Additionally, the company would need to simultaneously raise its full-year 2026 Adjusted EPS guidance beyond the current $17.70-$18.35 range, which currently implies approximately 10% growth at the midpoint. | Achieving mid-teens Adjusted EPS growth for Q2 and raising full-year guidance would signal accelerating operational efficiency and successful execution of strategic initiatives. This would differentiate Labcorp in a competitive market, validate its investment thesis, and potentially lead to a higher valuation multiple as investors gain confidence in its long-term profitability and ability to overcome industry headwinds. | |
| Diagnostics Segment Revenue Growth (Organic) | 2.9% | As the largest revenue contributor, organic growth in Diagnostics reflects core market demand, successful strategic initiatives like specialty testing, and the impact of acquisitions. | For Labcorp's stock to rerate higher, its Diagnostics Segment Revenue Growth (Organic) metric needs to hit 5% or higher. This would represent a significant acceleration from the 2.9% reported in Q1 2026 and demonstrate that Labcorp is effectively capitalizing on market opportunities, especially when compared to its peer Quest Diagnostics' recent Q2 2026 organic revenue growth of 10.0%. | Achieving 5% or higher organic growth in the Diagnostics segment is crucial as it signifies that Labcorp's strategic initiatives, such as expanding specialty testing and hospital partnerships, are successfully driving core business performance. This acceleration would validate the company's growth thesis, enhance its competitive standing against peers, and likely lead to a higher valuation multiple from investors. | |
Key QuestionsCan Labcorp's Biopharma Laboratory Services (BLS) segment deliver a sequential improvement in its quarterly book-to-bill ratio in Q2 2026, and will its trailing
Can Labcorp's Biopharma Laboratory Services (BLS) segment deliver a sequential improvement in its quarterly book-to-bill ratio in Q2 2026, and will its trailing 12-month book-to-bill remain above 1.0, validating future revenue growth?
- Question 2
Will Labcorp successfully execute on its active pipeline of hospital and regional laboratory acquisitions and partnerships, and can its specialty diagnostics areas (oncology, neurology) maintain their accelerated growth rates, driving overall Diagnostics segment performance?
- Question 3
What will be the initial indications of hospital and other laboratory participation in the ongoing PAMA data reporting survey, and will there be tangible progress on the RESULTS Act to mitigate potential future reimbursement pressures on Labcorp's Diagnostics business?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Being a partner of choice for health systems and regional/local laboratories:** Management emphasized expanding patient and provider networks, increasing access to their broad test portfolio (including specialty diagnostics), and driving volume growth through strategic collaborations and acquisitions, such as with Children's Hospital of Philadelphia and Crouse Health. 2. **Leading in specialty testing:** The company is focused on key growth areas like oncology, women's health, neurology, and autoimmune disease, expecting these areas to grow 2 to 3 times faster than the broader diagnostics market. They highlighted double-digit growth in neurology (driven by Alzheimer's testing) and oncology (supported by liquid biopsy tests and MRD solutions). 3. **Utilizing advanced technologies, including AI and robotics:** Management is focused on leveraging these technologies to enhance customer experiences and improve operational efficiency and productivity. Examples include expanding collaboration with PathAI for digital pathology, developing an AI-powered real-world data platform with Amazon Web Services and Datavant for Alzheimer's research, and a strategic collaboration with Optum.ai to streamline laboratory operations. | The overall takeaway of the call was positive, with Labcorp reporting a strong start to 2026, marked by solid revenue growth and margin expansion across both its Diagnostics and Biopharma Laboratory Services segments. Management expressed confidence in their strategic priorities, including partnerships with health systems, leadership in specialty testing, and the adoption of advanced technologies like AI. The company raised its full-year 2026 guidance, reflecting optimism for continued profitable growth and disciplined capital deployment. The tone was confident and optimistic. | In Q4 2025, enterprise revenue increased 5.6%. Diagnostics Laboratories segment revenue increased 5.5%. Biopharma Laboratory Services (BLS) revenue rose 3.4%, with Central Labs revenue growing 11.1% and Early Development revenue declining 13.5%. | 1. **Impact of weather and ACA exchange on Diagnostics volume:** Analysts questioned the impact of adverse weather in Q1 and potential headwinds from the ACA exchange. Management estimated a $15 million impact from weather, which would have brought organic volume growth closer to 2% without it. For ACA, they maintained their full-year estimate of a 30 basis point volume impact, noting the Q1 impact was immaterial but they continue to monitor enrollment and utilization. 2. **Bookings trends in BLS, especially Central Labs vs. Early Development, and confidence in future book-to-bill:** Analysts inquired about the BLS bookings and the quarterly book-to-bill ratio. Management expressed confidence in the BLS momentum, particularly Central Labs' growth, and stated that the Q1 book-to-bill of 0.94 was primarily due to timing, expecting sequential improvement in Q2 and a full-year book-to-bill to remain above 1.0. 3. **PAMA survey and RESULTS Act progress:** Analysts asked for updates on the PAMA survey and the RESULTS Act. Management reiterated their support for the RESULTS Act as the appropriate path forward and is awaiting a CBO score and CMS technical assistance. They noted that Labcorp would submit its data for PAMA, and the impact would depend on the number of other laboratories (including hospital labs) that also report, as more reporting would lessen the impact on Labcorp. | Enterprise revenue increased 5.8%. Diagnostics revenue increased 5%. Biopharma Laboratory Services (BLS) revenue increased 8.2%, driven by strong growth in Central Labs of 11% (or 4.9% organic constant currency). Early Development revenue grew 0.7% on an organic constant currency basis, partially offset by strategic actions of 1%. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Labcorp announced a nationwide strategic collaboration with Children's Hospital of Philadelphia to expand access to cutting-edge diagnostics for pediatric patients. The company completed its acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement to manage their inpatient laboratories. Labcorp is also on track to close its acquisition of select outreach laboratory services from Parkview Health in Indiana and Northwest Ohio. The company maintains an active pipeline of hospital and regional local laboratory deals to support long-term growth. Specialty testing in oncology, women's health, neurology, and autoimmune disease is a key focus, with these areas expected to grow 2 to 3 times faster than the broader diagnostics market. Labcorp is collaborating with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings, and expanded nationwide access to an FDA-approved companion diagnostic for platinum-resistant ovarian cancer. The company also launched the Labcorp Fentanyl Urine Visual Test. In Consumer Health, which is delivering double-digit growth, Labcorp OnDemand launched new tests for insulin resistance and pancreatic function, as well as customizable men's and women's health tests. The MyLabcorp secure mobile app, launching in May, will provide personalized test results and health data with clinical guidance to tens of millions of customers, and its AI assistant will simplify appointment scheduling and payments. | The CRO market remains highly competitive, with aggressive pricing dynamics described as a 'knife fight every quarter,' and unfavorable mix shifts continuing to impact margins across the industry. Labcorp is supportive of initiatives like CRUSH that aim to create a level playing field by reducing fraud, waste, and abuse in the industry. In the consumer business, Labcorp has opted not to compete in some segments due to strong volume at current pricing without a clear floor for pricing, indicating competitive pressures in those areas. | The broader industry is grappling with policy questions such as the CRUSH initiative by CMS, which aims to reduce fraud, waste, and abuse in laboratory testing. Labcorp supports efforts to create a level playing field but encourages CMS to be thoughtful to avoid impeding Medicare patient access to medically necessary testing. The company continues to monitor the impact of ACA exchange changes, with a 30 basis point volume impact to diagnostics still estimated for the full year 2026, despite immaterial impact in Q1. Labcorp is actively pushing for the implementation of the RESULTS Act, which aims to provide a long-term permanent fix for PAMA. The impact of PAMA on Labcorp will depend heavily on the number of other laboratories, including hospital laboratories, that report their data. The biopharma trial volume is rebounding, supported by biotech funding recovery and increased R&D investment and outsourcing by large pharmaceutical companies. Geopolitical factors are driving the re-shoring of Master Service Agreements (MSAs) to Western CROs. There is also an accelerated AI integration and deployment in CRO operations, driving efficiency and accelerating drug discovery. | Labcorp is raising the midpoint of its enterprise revenue range by approximately $30 million and the midpoint of its EPS range by $0.13 for the full year 2026. The company expects specialty areas in Diagnostics to grow 2 to 3 times faster than the broader diagnostics market. The MyLabcorp mobile app is launching in May. Labcorp is expanding its collaboration with PathAI to deploy an FDA-cleared digital pathology platform and is developing a new AI-powered real-world data platform with Amazon Web Services and Datavant to accelerate Alzheimer's research. A strategic collaboration with Optum.ai will apply AI capabilities to streamline laboratory operations and enhance patient and provider experiences. Strategic actions in the Early Development business are expected to be largely complete by the end of the second quarter. The BLS segment's quarterly book-to-bill is expected to improve sequentially in the second quarter and remain above 1 for the rest of the year. Labcorp will hold an Investor Day in New York City on September 10. The company remains focused on higher-margin business and is optimistic about its growth prospects and strategic priorities. Adam Schechter believes that if PAMA is implemented in January, it will likely increase the pipeline of deals for local and regional laboratories due to increased stress on these systems. Labcorp will continue to invest in bringing new products to market and in appropriate advertising for its OnDemand consumer business. | CROs: | The integration of advanced technologies, particularly Artificial Intelligence (AI) and robotics, is a significant emerging theme across the industry. Labcorp is utilizing AI to enhance customer experiences (e.g., MyLabcorp's AI assistant), improve operational efficiency and productivity (e.g., digital pathology platform with PathAI, streamlining laboratory operations with Optum.ai), and accelerate drug development (e.g., AI-powered real-world data platform for Alzheimer's research with AWS and Datavant). | We are off to a strong start in 2026 with continued momentum in both our Diagnostics and Central Laboratory businesses and significant progress across our strategic growth priorities. Our financial results were strong in the first quarter. At an enterprise level, revenue reached $3.5 billion, increasing 6%. Margins improved more than 30 basis points and adjusted earnings per share grew 11%. We continue to have an active pipeline of hospitals and regional local laboratory deals to support our long-term growth strategy. In the Diagnostic business, we expect these specialty areas to grow 2 to 3x faster than the broader diagnostics market. Labcorp supported the development of more than 85% of new drugs approved by the FDA last year, including in these important specialty areas. Consumer Health, where we continue to deliver double-digit growth. MyLabcorp brings an individual test results and health data together with clinical guidance into a personalized experience to help consumers better understand their test results. MyLabcorp's AI assistant will also help simplify appointment scheduling and payments. Our BLS trailing 12-month book-to-bill remains healthy at 1.04. We are raising the midpoint of the enterprise revenue range by approximately $30 million and the midpoint of the EPS range by $0.13. We remain confident in our ability to deliver durable growth and long-term value for our shareholders. I am optimistic about our growth prospects before us and the strategic priorities that we've put in place. | Volume was constrained by the impact from adverse weather, excluding which organic volume growth would have been closer to 2%. The impact that we saw in the first quarter was really immaterial, although it is perhaps too early to be able to draw any firm conclusion. The CRO market remains highly competitive, with aggressive pricing dynamics described as a 'knife fight every quarter,' and unfavorable mix shifts continuing to impact margins across the industry. In those areas, the reimbursement aren't necessarily quite where we'd like them to be at the moment. We've decided at this moment, there are some parts of it that although there is strong volume at the current pricing and not knowing the floor of the pricing that we're not necessarily going to compete at this time. The impact of PAMA of the RESULTS Act does not go through this year and PAMA actually comes to fruition next year, the impact to Labcorp will be highly dependent upon the number of other laboratories, including hospital laboratories that report their data. The estimated AOI impact is approximately $5 million to $10 million this year. | Dewey Steadman joined Labcorp in March as Senior Vice President of Investor Relations. Christin O'Donnell transitioned from leading Investor Relations to an important senior role in finance within the precision oncology and health systems division. Labcorp was recognized by Fortune as one of the most innovative companies for the fourth year in a row, highlighting its track record of scientific product and process innovations, which implies a workforce capable of driving such innovation. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| LH_538b9123 | September 10 | 2026-09-10 | 2026-09-10 | Labcorp Investor Day in New York City. | Management will share more details about their strategy, which could provide insights into future growth drivers, capital allocation, and operational improvements, potentially impacting investor sentiment and stock valuation. | Ticker | 2026-04-30 | earnings_transcript |
| LH_e2f765c4 | in the very near future | 2026-07-24 | 2026-10-24 | Completion of the acquisition of select outreach laboratory services across Indiana and Northwest Ohio from Parkview Health. | This acquisition will expand Labcorp's patient and provider networks, increase access to its broad test portfolio, and drive volume growth for the Diagnostics business, positively impacting revenue and competitive position. | Ticker | 2026-04-30 | earnings_transcript |